Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Radiotherapy With or Without Cisplatin and Fluorouracil for Locally Advanced, Nonresectable Squamous Cell Cancer of the Oropharynx or Hypopharynx
NCT00003627Phase 3Completed
- Sponsor
- Unicancer
- Start
- Oct 1998
- Primary completion
- Dec 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of cisplatin and fluorouracil in oropharyngeal squamous cell carcinoma (OPSCC) and hypopharyngeal squamous cell carcinoma (HSCC) (2 arms), sponsored by Unicancer. Primary endpoints: Overall Survival at 5 years and Survival Without Relapse at 5 years. Started Oct 1998; status: completed.
02
Drugs
cisplatinfluorouracil
03
Conditions
oropharyngeal squamous cell carcinoma (OPSCC)hypopharyngeal squamous cell carcinoma (HSCC)
Beyond the preview
Go deeper on NCT00003627.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00003627.